Drug
LTT462
LTT462 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/3)
Active Trials
1(25%)
Terminated
3(75%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 3 finished
Non-Completion Rate
100.0%
3 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Terminated(3)
Detailed Status
Terminated3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
active_not_recruiting125%
terminated375%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621
terminatedphase_1
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
NCT04294160
terminatedphase_1
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT02974725
terminatedphase_1
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
NCT02711345
Clinical Trials (4)
Showing 4 of 4 trials
NCT04417621Phase 2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04294160Phase 1
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
NCT02974725Phase 1
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT02711345Phase 1
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4